
Sign up to save your podcasts
Or


This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
By ReachMD4.3
33 ratings
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.